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Disseminated bacille Calmette–Guérin disease in HIV-infected 
South African infants
AC Hesseling,a LF Johnson,b H Jaspan,c MF Cotton,c A Whitelaw,d HS Schaaf,c PEM Fine,e BS Eley,f BJ Marais,a 
J Nuttall,f N Beyers a & P Godfrey-Faussett g
Objective To determine the population-based incidence of disseminated bacille Calmette–Guérin (BCG) disease in HIV-infected infants 
(aged £ 1 year) in a setting with a high burden of tuberculosis and HIV infection coupled with a well-functioning programme for the 
prevention of HIV infection in infants.
Methods The numerator, or number of new cases of disseminated BCG disease, was derived from multicentre surveillance data 
collected prospectively on infants with a confirmed HIV infection during 2004–2006. The denominator, or total number of HIV-infected 
infants who were BCG-vaccinated, was derived from population-based estimates of the number of live infants and from reported 
maternal HIV infection prevalence, vertical HIV transmission rates and BCG vaccination rates.
Findings The estimated incidences of disseminated BCG disease per 100 000 BCG-vaccinated, HIV-infected infants were as follows: 
778 (95% confidence interval, CI: 361–1319) in 2004 (vertical HIV transmission rate: 10.4%); 1300 (95% CI: 587–2290) in 2005 
(transmission rate: 6.1%); and 1013 (95% CI: 377–1895) in 2006 (transmission rate: 5.4%). The pooled incidence over the study 
period was 992 (95% CI: 567–1495) per 100 000.
Conclusion Multicentre surveillance data showed that the risk of disseminated BCG disease in HIV-infected infants is considerably 
higher than previously estimated, although likely to be under-estimated. There is an urgent need for data on the risk–benefit ratio of 
BCG vaccination in HIV-infected infants to inform decision-making in settings where HIV infection and tuberculosis burdens are high. 
Safe and effective tuberculosis prevention strategies are needed for HIV-infected infants.
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Introduction
Vaccination with bacille Calmette-Guérin (BCG), a live at-
tenuated strain of Mycobacterium bovis, is almost universally 
given in sub-Saharan African countries where the brunt of 
the global burden of paediatric infection with type-1 HIV is 
concentrated. The Joint United Nations Programme on HIV/
AIDS (UNAIDS) estimates that 390 000–420 000 children 
< 15 years of age acquire HIV infection each year.1 BCG vac-
cination is usually given at birth or in the perinatal period. 
In 2002, an estimated 75% of the 130 million children born 
worldwide were vaccinated with BCG.2
BCG has consistent efficacy for the prevention of dissemi-
nated tuberculosis in young children without HIV infection. 
A recent meta-analysis has shown a summary protective BCG 
effect of 73% (95% confidence interval, CI: 67–79) against 
tuberculous meningitis and 77% (95% CI: 58–87) against 
miliary tuberculosis.2 In contrast, there is limited evidence 
that BCG has a protective effect in HIV-infected infants 
and children.3,4 In South Africa, the reported incidence of 
culture-confirmed tuberculosis among HIV-infected infants 
is 1596 per 100 000 (95% CI: 115–2132), a rate 24.2 times 
higher than among infants not infected with HIV.5 It is pos-
sible that HIV-related suppression of T cells compromises 
specific T-cell mediated immune responses and reduces BCG 
efficacy in infants.
Adverse events linked to BCG vaccination range from 
mild, localized complications to more serious, systemic or 
disseminated BCG disease in which M. bovis BCG is con-
firmed in one or more anatomical sites far from both the 
site of injection and regional lymph nodes.6 Disseminated 
BCG disease is associated with a case-fatality rate of > 70% 
in infants.6, 7 By comparison, the background mortality rate 
among South African HIV-infected infants is 12.2 per 100 
person-years (95% CI: 8.2–17.4).8
Systemic or disseminated BCG disease may be clini-
cally indistinguishable from tuberculosis and can only be 
confirmed through positive mycobacterial culture species 
identification, preferably by polymerase chain reaction (PCR) 
for the RD1 genetic region that is lost during attenuation of 
BCG.9
While the documented risk of disseminated BCG disease 
in non-HIV-infected infants is < 5 per 1 million vaccinees 
and is associated with rare congenital immune deficiencies,10 
it has been shown to be 1100 to 4170 per 1 million in HIV-
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infected infants routinely vaccinated 
at birth.3,11 Consequently, in 2007 the 
WHO Global Advisory Committee 
on Vaccine Safety and the Strategic 
Advisory Group of Experts recom-
mended revising BCG vaccination 
policy for HIV-infected infants.12,13 
This milestone recommendation and 
the ensuing change in policy14 have 
resulted in HIV infection becoming 
a full contraindication for BCG vac-
cination in infants, even in those who 
are asymptomatic at birth and at risk 
of Mycobacterium tuberculosis infection 
early in life. In preceding years, WHO 
advised increasing caution on the use 
of BCG in HIV-infected children, 
following case reports of disseminated 
BCG disease.3,6,7,15 WHO also called 
for more epidemiological data on the 
true impact of serious BCG adverse 
events and for closer monitoring of 
these events in areas of high HIV infec-
tion prevalence, with a specific focus 
on distinguishing BCG infection from 
disease caused by M. tuberculosis.12,13 
In light of the limited data available 
to inform the discussion of BCG risks 
and benefits in HIV-infected infants, 
we conducted a multicentre surveillance 
study to estimate more accurately the 
population incidence of disseminated 
BCG disease in HIV-infected infants 
in a setting where tuberculosis and 
HIV infection are highly endemic and 
universal neonatal BCG vaccination is 
practiced.
Methods
Study setting and design
This multicentre prospective hospital-
based surveillance study was conducted 
between 1 January 2004 and 31 Decem-
ber 2006 in the three paediatric referral 
hospitals that service the Western Cape 
Province, South Africa: Tygerberg Chil-
dren’s Hospital, Red Cross Children’s 
Hospital and Groote Schuur Hospital. 
These hospitals have specialist paediat-
ric HIV services and routinely perform 
mycobacterial culture in children with 
suspected mycobacterial disease in 
conjunction with speciation of M. tu-
berculosis complex isolates. Routine 
prospective laboratory surveillance for 
BCG-related adverse events was initi-
ated following earlier case reports of 
serious BCG complications in HIV-
infected infants.6
In South Africa, universal BCG 
vaccination of infants at birth was 
implemented in 1973. Most infants are 
born in health-care centres. Since 2000, 
intradermal vaccination with the M. bo-
vis Danish strain 1331 (Statens Serum 
Institute, Copenhagen, Denmark) is 
administered in the right deltoid region. 
In 2005, neonatal vaccination coverage 
was 98–99% in the province16 and the 
overall tuberculosis incidence was 917 
per 100 000 total population.17  In 
2006, the HIV infection prevalence 
among pregnant women in the public 
health sector was 15.1% (95% CI: 
11.6–18.7).18 There is a well-established 
public programme for the preven-
tion of mother-to-child transmission 
(PMTCT) of HIV. HIV testing is 
offered universally to women at their 
first antenatal visit. During 2004–2005, 
dual therapy with zidovudine and 
nevirapine was used for PMTCT in 
both mothers and infants. From 2006 
onwards, zidovudine was initiated at 
28 weeks of pregnancy rather than 34 
weeks. Currently, women whose CD4+ 
T-lymphocyte (CD4) count is £ 200 
cells/mm3 are fast-tracked for highly 
active antiretroviral therapy (HAART). 
All HIV-infected women are provided 
with free milk powder for 6 months 
if they choose to formula-feed. Infant 
HIV testing was offered at 14 weeks 
of age with a single HIV-DNA PCR 
test and infants were followed for 
6 months until discharged from the 
PMTCT programme. The reported 
vertical HIV transmission rate varied 
from 5.4% to 10.4% during the study 
period, a reflection of variations in the 
introduction, uptake and performance 
of PMTCT regimens. The uptake of 
maternal antenatal HIV testing dur-
ing 2006 was 93.0%; around 90% of 
women exclusively fed their infants us-
ing formula (data from Western Cape 
Department of Health).
This study was approved by the 
research ethics committees of Stel-
lenbosch University and the University 
of Cape Town. Study implementation 
and reporting adhered to STROBE 
(Strengthening the Reporting of Ob-
servational studies in Epidemiology) 
guidelines.19
Incidence of disseminated BCG 
disease
As disseminated BCG disease is pre-
dominantly seen in HIV-infected chil-
dren £ 1 year of age and who exhibit 
rapid progression to advanced HIV 
disease, 3, 6, 7 all HIV-infected children 
£ 1 year of age (infants) diagnosed with 
disseminated BCG disease during the 
study period were eligible for inclusion. 
The incidence of disseminated BCG 
disease was calculated as previously de-
scribed.11 In addition, CIs were derived 
from multiple sources of uncertainty 
and actual reported, rather than esti-
mated rates of vertical HIV transmission 
were used. Two cases were included in 
a previous report from Tygerberg Chil-
dren’s Hospital.11
Case definitions and data collection
Systemic or disseminated BCG disease 
was defined as the isolation of M. bovis 
BCG from one or more clinical samples 
− regional lymph nodes, respiratory 
secretions, blood, bone marrow or ce-
rebrospinal fluid − taken at sites distant 
from the vaccination site, in the pres-
ence of a clinical syndrome consistent 
with disseminated BCG disease.6 Pa-
tient data were obtained from hospital 
and laboratory records. Mycobacterial 
culture and HIV testing were routinely 
performed at the discretion of attending 
physicians. The automated Middle-
brook 7H9 broth-based Mycobacterial 
Growth Indicator Tube culture system 
(Becton-Dickinson, Hunt Valley, MD, 
United States) was used for mycobac-
terial culture; the identification of 
an isolate as M. bovis BCG was con-
firmed using a multiplex PCR assay 
that distinguishes M. bovis BCG from 
other members of the M. tuberculosis 
complex.9 The date on which the my-
cobacterial culture sample was obtained 
was used to calculate patient age. Infant 
HIV infection status was determined 
using HIV-DNA PCR.
Incidence
The numerator for calculating the in-
cidence of disseminated BCG disease 
was the total estimated number of 
HIV-infected infants diagnosed with 
such disease at the three study hos-
pitals during the study period. Those 
with disease caused by M. tuberculosis 
or nontuberculous mycobacteria were 
excluded. The denominator was the 
estimated annual number of HIV-
infected BCG-vaccinated infants in 
Western Cape Province, which was 
obtained from different data sources in 
the absence of reliable population data 
on infants in the province. Data for 
the Western Cape from the Actuarial 
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Society of South Africa’s 2003 AIDS 
and demographic model were used to 
estimate the total number of person-
years of observation for all infants.20,21 
This model provides a projection of 
the population of South Africa by age, 
sex, race, province and HIV status and 
allows for the effect of AIDS on mortal-
ity and fertility rates. It is calibrated to 
census data, demographic and health 
survey data, and data on recorded 
deaths and HIV infection prevalence 
in national surveys. The proportion 
of the total number of person-years of 
observation that corresponded to HIV-
infected infants was estimated using the 
prevalence of maternal HIV infection 
in the province in conjunction with 
vertical HIV transmission rates reported 
by the PMTCT programme. Finally, 
the reported BCG vaccination coverage 
rate was used to estimate the number of 
HIV-infected BCG-vaccinated infants 
at risk of disseminated BCG disease.
Confidence intervals
The CIs for the incidence rates were 
estimated through a bootstrap ap-
proach in which the three key quanti-
ties used to calculate the incidence rate 
were treated as independent random 
variables. Values for the number of 
cases of disseminated BCG disease were 
sampled from a Poisson distribution 
that had the same mean as the observed 
number of cases; values for the HIV 
prevalence were sampled from b distri-
butions based on means and standard 
deviations determined from published 
antenatal prevalence estimates and as-
sociated CIs; and values for mother-to-
child transmission rates were sampled 
from b distributions based on reported 
mother-to-child transmission rates and 
associated sample sizes. The sampling 
procedure was repeated 10 000 times for 
each incidence estimate and bootstrap 
CIs were obtained using the percentile 
method.22
Results
In total, 32 cases of disseminated BCG 
disease were confirmed in HIV-infected 
infants during the study period: 12 in 
2004, 12 in 2005 and 8 in 2006. All 
were included in the study analysis. No 
cases were observed in infants without 
HIV infection or with unknown HIV 
status. Of HIV-infected infants, 53 
had disease due to M. tuberculosis and 
11 had disease due to nontuberculous 
mycobacteria; these were excluded from 
analysis.
Table 1 shows the number of in-
fants with disseminated BCG disease, 
the estimated number of infants with 
HIV infection, and the estimated in-
cidence of disseminated BCG disease 
in these infants. Figures are for the 
Western Cape Province for the years 
2004–2006. The estimated incidence 
per 100 000 HIV-infected, BCG-
vaccinated infants was as follows: 778 
(95% CI: 361–1319) in 2004 (esti-
mated vertical HIV transmission rate: 
10.4%); 1300 (95% CI: 587–2290) 
in 2005 (estimated transmission rate: 
6.1%); and 1013 (95% CI: 377–1895) 
in 2006 (estimated transmission rate: 
5.4%). The pooled estimate for the 
incidence of disseminated BCG disease 
over the entire study period was 992 
per 100 000 (95% CI: 567–1495). The 
infants’ mean age at presentation was 
Table 1. Estimated incidence of disseminated BCG disease in HIV-infected infants (aged £ 1 year) vaccinated at birth with BCG, 
Western Cape Province, South Africa
Year
2004 2005 2006
No. of cases of disseminated BCG disease in HIV-infected infants 
£ 1 year of age
12 12 8
Estimated total no. of infants £ 1 year of age 98 236 98 339 98 137
Provincial maternal HIV prevalence (% and 95% CI) 15.4 (12.5–18.2) 15.7 (11.3–20.1) 15.2 (11.6–18.7)
Reported vertical HIV transmission rate (%) 10.4 6.1 5.4
Estimated total no. of HIV-infected infants 1573 942 806
Estimated incidence of disseminated BCG diseasea, assuming 
98–99% BCG vaccination coverage (no. and 95% CI)
778 (361–1319) 1300 (587–2290) 1013 (377–1895)
BCG, bacille Calmette-Guérin; CI, confidence interval.
a  Per 100 000 HIV-infected vaccinated infants. The pooled estimate for the incidence of disseminated BCG disease over the entire study period was 992 per 100 000 
HIV-infected, BCG-vaccinated infants (95% CI: 567–1495).
9 months (range: 1–12 months); 25 of 
the 32 infants died, which resulted in 
an all-cause mortality rate of 78.1%. 
The median time to death following a 
diagnosis of disseminated BCG disease 
was 75 days (range: 0–359 days).
Discussion
We present population estimates of 
disseminated BCG disease in rou-
tinely vaccinated HIV-infected infants 
obtained through multicentre prospec-
tive surveillance. These data confirm 
that BCG vaccination in HIV-infected 
infants poses a risk of disseminated 
BCG disease that is approximately 
3- to 4-fold higher than the earlier 
preliminary estimates of 110–417 cases 
per 100 000 infants.11 The difference 
in risk estimates is most likely due to 
the inclusion in the present study of 
all three provincial referral hospitals 
instead of just one, as in the earlier 
study, while the denominator for the 
incidence calculation was derived by 
the same method. In addition, we used 
reported rates for vertical HIV trans-
mission in the study period rather than 
assumed rates of 5%, 10% and 15% 
in different scenarios.11 Our calcula-
tion of the CIs for the incidence rates 
was based on three known sources of 
uncertainty. Thus, the result is more 
likely to reflect the true uncertainty 
of the incidence estimates. The low 
incidence of disseminated BCG disease 
found in infants without HIV infection 
is consistent with other reports.10,11
Our data support recently revised 
WHO recommendations against vacci-
nating HIV-infected infants with BCG. 
However, it is difficult to decide how 
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Box 1.  Four scenarios, outlined by WHO, that affect the balance of risks and benefits 
of BCG vaccination in settings with high burdens of tuberculosis and HIV 
infection14
1. Infants born to women of unknown HIV status
The benefits of BCG vaccination outweigh the risks, and infants should be vaccinated.
2. Infants whose HIV infection status is unknown and who demonstrate no sign or 
symptom of HIV infection, but who are born to women known to be HIV-infected
The benefits of BCG vaccination usually outweigh the risks, and infants should receive the 
vaccine after consideration of local factors.
3. Infants who are known to be HIV-infected, with or without signs or symptoms of 
HIV infection
The risks of BCG vaccination outweigh the benefits and infants should not receive the vaccine, 
but they should receive other routine vaccines.
4. Infants with unknown HIV infection status but who have signs or symptoms of HIV 
infection and were born to HIV-infected mothers
The risks of BCG vaccination usually outweigh the benefits, and children should not be 
vaccinated during the first few weeks of life, since clinical symptoms of HIV infection typically 
occur after 3 months of age. However, the vaccine can be given if HIV infection is ruled out by 
early virological testing.
BCG, bacille Calmette-Guérin.
to defer BCG vaccination selectively 
in all infants born to HIV-infected 
women in settings with high burdens of 
HIV and tuberculosis. The risk of dis-
seminated BCG disease in the relatively 
small number of HIV-infected infants 
must be balanced against the risk of 
not vaccinating infants without HIV 
infection, who remain the vast majority 
of infants.23
Recently, WHO has emphasized 
that application of the revised BCG 
vaccination guidelines will depend on 
local factors,14 including the risk of ex-
posure to M. tuberculosis, the prevalence 
of tuberculosis and HIV infection, the 
efficacy of programmes for PMTCT 
of HIV, breastfeeding patterns, and 
the ability to follow up immunized 
children and perform early virological 
testing. Other requirements include a 
good tuberculosis surveillance system 
for pregnant women and their infants 
and well-functioning integrated services 
for infant immunization and the treat-
ment of HIV-infected children. WHO 
outlined four specific scenarios that af-
fect the balance of risks and benefits of 
BCG vaccination in a setting with high 
tuberculosis and HIV infection burdens 
and these scenarios are listed in Box 1.
Implementation of the revised 
BCG vaccination guidelines is likely 
to be challenging, even with well-
functioning PMTCT programmes 
and good diagnostic facilities, as most 
HIV transmission occurs peripartum 
or postpartum. The sensitivity of a 
single HIV-DNA PCR test performed 
< 48 hours after birth is < 40% but 
increases to > 90% at 2–4 weeks.24 In 
South Africa and many other develop-
ing countries, HIV PCR testing is per-
formed only after 6 weeks, if at all. A 
key consideration is therefore whether 
infant vaccination and PMTCT pro-
grammes are able to selectively delay 
the BCG vaccination of HIV-exposed 
infants until 10–14 weeks after birth, 
for example, until a negative HIV-DNA 
PCR test result is obtained at a routine 
vaccination visit. Delayed vaccination 
could be combined with an alternative 
tuberculosis prevention strategy, such as 
isoniazid treatment. Such an approach 
would require close collaboration with 
other health programmes and an inte-
grated PMTCT and infant vaccination 
programme with adequate follow-up.
Better prevention of maternal and 
infant HIV infection and more rapid 
access to HAART for those infected is 
likely to reduce the infant population 
at risk of disseminated BCG disease as 
well as the risk of severe vaccine com-
plications in HIV-infected infants. The 
International Union against Tubercu-
losis and Lung Disease BCG Working 
Group has recently issued a consensus 
statement on the use of BCG vaccina-
tion in countries where HIV infection 
and tuberculosis are highly prevalent.25
Although data on the risk of dis-
seminated BCG disease in infants on 
HAART are lacking, a recent study 
demonstrated that giving HAART to 
HIV-infected infants £ 12 weeks of age 
reduced all-cause mortality and tuber-
culosis in the first year of life, unlike 
deferring HAART until standard HIV 
symptomatic or CD4 criteria were 
met.8 In addition, the incidence of re-
gional BCG complications was lower.26
The available data therefore indi-
cate a considerable risk of both tuber-
culosis and serious BCG complications 
in HIV-infected infants, while there is 
little evidence that BCG vaccination is 
beneficial in such infants. In contrast, 
most infants without HIV infection 
benefit from BCG vaccination and are 
at a low risk of serious vaccine compli-
cations. Little is known about the pro-
tective efficacy of BCG vaccination in 
infants exposed to HIV but not HIV-
infected or who may be at high risk of 
tuberculosis because of immunological 
factors or a high maternal risk of tuber-
culosis.27,28,29 BCG vaccination should 
be offered to HIV-unexposed infants 
once HIV infection has been ruled out.
The study has several limitations. 
Firstly, it is likely that numerator data 
were considerably underestimated, 
as not all HIV-infected infants with 
disseminated BCG disease in the prov-
ince would have been referred to and 
investigated in the three study hospi-
tals. In addition, cases may have been 
missed because mycobacterial disease 
in children is usually paucibacillary. 
Secondly, the denominator – the num-
ber of BCG-vaccinated HIV-infected 
infants – may have been overestimated. 
In particular, HIV infection prevalence 
estimates were obtained only for preg-
nant women attending public health 
facilities; the prevalence is likely to be 
lower in those attending private health 
facilities, among whom vertical trans-
mission will also be lower due to bet-
ter access to treatment. On the other 
hand, the denominator may have been 
underestimated, as it was derived using 
vertical HIV transmission rates reported 
by the provincial PMTCT programme, 
which may have been biased by incom-
plete uptake of maternal HIV testing 
and PMTCT, loss to follow-up, inad-
equate testing of HIV-exposed infants 
or missing data. In 2006, an estimated 
93% of mothers were tested for HIV 
and 74.7% of infants were tested at or 
after 14 weeks. The large CIs reported 
in the present study reflect uncertain-
ties in the vertical HIV transmission 
rate and maternal HIV infection preva-
lence. Our survey should also be rep-
licated in other settings with different 
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levels of mycobacterial exposure and 
susceptibility to tuberculosis and HIV 
infection. In our study, disseminated 
BCG disease was due to Danish strain 
1331 BCG. Vaccine strain may influ-
ence BCG-related adverse events and 
should be considered when these are 
monitored and reported.30,31 We did not 
have data available on the incidence of 
tuberculosis among non-vaccinated 
HIV-infected infants, since routine vac-
cination coverage was almost universal.
In conclusion, the risk of dissemi-
nated BCG disease was high in HIV-
infected infants routinely vaccinated at 
birth in a setting with high tuberculosis 
and HIV burdens and a well-function-
ing PMTCT programme. However, 
there are operational obstacles to se-
lectively deferring BCG vaccination in 
infants born to HIV-infected women. 
Since not vaccinating an infant who is 
exposed to HIV but remains uninfected 
may increase the risk of disseminated 
tuberculosis, BCG vaccination should 
continue in settings where HIV infec-
tion and tuberculosis are both highly 
endemic until it is feasible to imple-
ment a policy of selective vaccination. 
Clear goals should be established for 
the implementation of safe vaccination 
practices in HIV-infected infants and 
for reducing the burden of maternal 
and infant tuberculosis. More data 
are needed on the protective effect of 
BCG vaccination in HIV-infected in-
fants and in HIV-exposed uninfected 
infants, as well as on the operational 
feasibility of deferred BCG vaccina-
tion in HIV-exposed infants. Safe and 
effective antituberculosis preventive 
strategies, including effective vaccines, 
are urgently needed for HIV-infected 
infants.  ■
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Résumé
Infection disséminée par le bacille de Calmette-Guérin chez les nourrissons infectés par le VIH d’Afrique du Sud
Objectif Déterminer l’incidence en population de l’infection 
disséminée par le bacille de Calmette-Guérin (BCG) chez les 
nourrissons infectés par le VIH (âge £ 1 an) dans une situation 
caractérisée par une forte charge de tuberculose et d’infections 
à VIH, mais aussi par un bon fonctionnement du programme de 
prévention de l’infection par le VIH chez les nourrissons.
Méthodes Le numérateur, ou nombre de nouveaux cas d’infection 
disséminée par le BCG, a été déterminé à partir des données de 
surveillance multicentrique, collectées prospectivement au sujet 
des nourrissons présentant une infection à VIH confirmée au cours 
de la période 2004-2006. Le dénominateur, ou nombre total de 
nourrissons infectés par le VIH et vaccinés par le BCG, a été obtenu 
à partir d’estimations en population du nombre de nourrissons 
vivants et à partir de la prévalence rapportée des infections à VIH 
maternelles, des taux de transmission verticale du VIH et des taux 
de vaccination par le BCG.
Résultats L’incidence de l’infection disséminée par le BCG pour 
100 000 nourrissons vaccinés par le BCG a été estimée à : 778 
cas (intervalle de confiance à 95 %, IC : 361-1319) en 2004 (taux 
de transmission verticale du VIH : 10,4 %) ; 1300 cas (IC à 95 % : 
587-2290) en 2005 (taux de transmission : 6,1 %) ; et 1013 cas 
(IC à 95 % : 377-1895) en 2006 (taux de transmission : 5,4 %). 
L’incidence globale sur l’ensemble de la période étudiée était de 
992 (IC à 95 % : 567-1495) pour 100 000.
Conclusion Les données de surveillance multicentrique ont 
montré que le risque d’infection disséminée par le BCG chez les 
nourrissons infectés par le VIH était considérablement plus élevé 
qu’on ne l’avait estimé auparavant, bien que probablement encore 
sous-estimé. On a besoin d’urgence de données sur le rapport 
risque/bénéfice de la vaccination par le BCG chez les nourrissons 
infectés par le VIH pour étayer la prise de décisions dans des 
contextes où les charges d’infection à VIH et de tuberculose sont 
importantes. Des stratégies sûres et efficaces de prévention de 
la tuberculose sont nécessaires pour les nourrissons infectés par 
le VIH.
Resumen
Infección diseminada por el bacilo de Calmette–Guérin en lactantes infectados por el VIH en Sudáfrica
Objetivo Determinar la incidencia poblacional de la infección 
diseminada por el bacilo de Calmette-Guérin (BCG) en lactantes 
(niños £ 1 años) en un entorno de alta carga de tuberculosis e 
infección por VIH y de aplicación satisfactoria de un programa de 
prevención de la infección por VIH en los lactantes.
Métodos El numerador, o número de nuevos casos de infección 
diseminada por BCG, se calculó a partir de datos de vigilancia 
multicéntricos reunidos prospectivamente sobre lactantes con 
infección confirmada por VIH durante 2004-2006. El denominador, 
o número total de lactantes infectados por el VIH y vacunados 
con la BCG, se calculó a partir de estimaciones poblacionales 
del número de lactantes vivos y de la prevalencia de infección 
materna por VIH, de las tasas de transmisión vertical del VIH y de 
las tasas de vacunación con BCG.
Resultados Las incidencias estimadas de infección diseminada 
por BCG  por 100 000 lactantes infectados por el VIH y vacunados 
con BCG fueron las siguientes: 778 (intervalo de confianza del 
95%, IC95%: 361–1319) en 2004 (transmisión vertical del VIH: 
10,4%); 1300 (IC95%: 587–2290) en 2005 (tasa de transmisión: 
6,1%); y 1013 (IC95%: 377–1895) en 2006 (tasa de transmisión: 
5,4%). La incidencia combinada a lo largo del periodo estudiado 
fue de 992 (IC95%: 567–1495) por 100 000.
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Conclusión Los datos de la vigilancia multicéntrica revelaron 
que el riesgo de infección diseminada por BCG en los lactantes 
infectados por el VIH era considerablemente superior al estimado 
anteriormente. Urge disponer de datos sobre la relación riesgo-
beneficio de la vacunación con BCG en los lactantes infectados 
por el VIH a fin de fundamentar la adopción de decisiones en los 
entornos con alta carga de infección por VIH y de tuberculosis. Es 
preciso formular estrategias seguras y eficaces de prevención de 
la tuberculosis para los lactantes infectados por el VIH.
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صخلم
ايقيرفأ بونج في زديلإا سويرفب ينباصلما لافطلأا ىدل شرتنلما نايرغ – تيلماك تايصع نع مجانلا ضرلما
 تايصع نع مجانلا  ضرملل  زكترلما  نياكسلا  عوقولا  لدعم ديدحت  :ضرغلا
 ينباصلما  )ةنس  نع  مهرماعأ  لقت  نيذلا(  لافطلأا  ىدل  نايرغ  –  تيلماك
 ىودعلاو لسلا نم ليقث ءبع نم نياعت يتلا عقاولما دحأ في زديلإا سويرفب
 لافطلأا  ىودع  نم  ةياقولل  ءادلأا  ةديج  جمارب  لظ في  ًاعم  زديلإا  سويرفب
.زديلإا سويرفب
 ةديدجلا تلااحلا ددع وأ )طسبلا( موسقلما ددعلا نوثحابلا دمتسا :ةقيرطلا
 في د ُّصرت تايطعم نم ،شرتنلما نايرغ – تيلماك تايصع نع مجانلا ضرملل
 سويرفب مهتباصإ تدكأت نيذلا لافطلأا نع ًايقابتسا تعمج ةد ِّدعتم زكارم
 لافطلأا تلااح ددع وأ )جرخلما( ماقلما امأ .2006 – 2004 ةدلما للاخ زديلإا
 دقف ،نايرغ – تيلماك تايصعب  ًاحيقلت اوقلت نيذلا زديلإا سويرفب ينباصلما
 راشتنا لدعم نمو ءايحلأا لافطلأا ددعل زكترلما ةيناكس تاريدقت نم دمتسا
 ةيدومعلا  ةياسرلا  تلادعم نمو هنع  غَّلبلما  زديلإا  سويرفب  تاهملأا  ىودع
.يج سي يبلاب حيقلتلا تلادعمو زديلإا سويرفب
 – تيلماك تايصع نع مجانلا ضرلما عوقول ر َّدقلما لدعلما غلب :تادوجولما
 سي يبلا حاقل اوقلتو زديلإا سويرفب ينباصلما لافطلأا نم فلأ ةئم لكل نايرغ
 ،2004 ماع في كلذو )1319و 361 ينب تحوارت %95 ةقث ةلصافب ،778 يج
 ،)2290 – 587 ينب تحوارت %95 ةقث ةلصافب( 1300 غلب 2005 ماع فيو
 مايف ،)1895و 337 ينب تحوارت ،%95 ةقث ةلصافب( 1013 غلب 2006 ماعو
 ماع فيو )%10.4( 2004 ماع في زديلإا سويرفل ةيدومعلا ةياسرلا لدعم غلب
 تاعوقولل يعيمجتلا لدعلما ناكو .)%5.4( 2006 ماع فيو ،)%6.1( 2005
 ينب  حوارت  ذإ  ،%95  ةقث  ةلصافب(  فلأ  ةئم  لكل  992  ةساردلا  ةترف  ةليط
.)1495 – 567
 رطخ نأ ةددعتم زكارم نم ةدمتسلما د ُّصترلا تايطعم ترهظأ دقل :جاتنتسلاا
 ينباصلما  لافطلأا  ىدل  شرتنلما  نايرغ  –  تيلماك  تايصع  نع  مجانلا  ضرلما
 ستمو  .لبق  نم  ًار َّدقم  ناك  مام  بركأ  لكشب  ًاعفترم  برتعي  زديلإا  سويرفب
 سي يبلا حاقلب ميعطتلل عفانلما لباقم رطاخلما ةبسن لوح تايطعملل ةجاحلا
 سيايسلا رارقلا باحصأ ديوزتل كلذو ،زديلإا سويرفب ينباصلما لافطلأل يج
 سويرفبو لسلاب ىودعلا نم لك ءبع اهيف عفتري يتلا عقاولما نع تامولعبم
 نم ةياقولل ةلاعفو ةنومأم تايجيتاترسا دوجو لىإ ةجاحلا ستم ماك .زديلإا
.زديلإا سويرفب ينباصلما لافطلأا ىدل لسلا
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